红细胞包裹的天冬酰胺酶用于对天冬酰胺酶超敏的急性淋巴细胞白血病患者的二线治疗
在NOR-GRASPALL 2016研究中,55例对聚乙二醇化天冬酰胺酶超敏的非高危急性淋巴细胞白血病患者接受红细胞包裹的天冬酰胺酶(eryaspase)治疗,以完成原定天冬酰胺酶疗程。首次输注后14±2天,49例(96.1%)患者天冬酰胺酶活性≥100 iu/l;5例(9.1%)出现与酶失活相关的临床过敏;50例(90.9%)成功完成替代治疗。eryaspase耐受良好,首次输注后多数患者天冬酰胺酶活性高于治疗目标,半衰期支持2周方案。
要点
- 首次eryaspase输注后14±2天,49例(96.1%)患者天冬酰胺酶活性≥100 iu/l。
- 5例(9.1%)出现与酶失活相关的临床过敏,50例(90.9%)成功完成替代治疗。
- 首次输注后平均终末半衰期为15.3±15.5天,支持2周给药方案。
核心结论
- eryaspase耐受良好,多数患者首次输注后天冬酰胺酶活性高于治疗目标。
- eryaspase的半衰期证实2周方案是合适的。
研究设计与样本
- NOR-GRASPALL 2016(NCT03267030)研究评估eryaspase在对聚乙二醇化天冬酰胺酶超敏的非高危急性淋巴细胞白血病患者中的安全性和有效性。
- 共纳入55例患者,年龄1-45岁,中位年龄6.1岁。
- eryaspase按150 u/kg给药,计划在两个北欧/波罗的海治疗方案中完成原定天冬酰胺酶疗程(1-7剂)。
主要发现
- 首次eryaspase输注后14±2天,49例(96.1%)患者天冬酰胺酶活性≥100 iu/l,中位活性511 iu/l(四分位距291-780)。
- 第四次输注后14±2天,9例患者中6例(66.7%)天冬酰胺酶活性≥100 iu/l,中位活性932 iu/l(四分位距496-163)。
- 首次输注后eryaspase平均终末半衰期为15.3±15.5天。
- 5例(9.1%)患者出现与酶失活相关的临床过敏。
- 50例(90.9%)患者成功完成替代治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Asparaginase is essential in treating acute lymphoblastic leukaemia (ALL). Asparaginase-related hypersensitivity causes treatment discontinuation, which is associated with decreased event-free survival. To continue asparaginase treatment after hypersensitivity, a formulation of asparaginase encapsulated in erythrocytes (eryaspase) was developed. In NOR-GRASPALL 2016 (NCT03267030) the safety and efficacy of eryaspase was evaluated in 55 patients (aged 1-45 years; median: 6.1 years) with non-high-risk ALL and hypersensitivity to asparaginase conjugated with polyethylene glycol (PEG-asparaginase). Eryaspase (150 u/kg) was scheduled to complete the intended course of asparaginase (1-7 doses) in two Nordic/Baltic treatment protocols. Forty-nine (96.1%) patients had asparaginase enzyme activity (AEA) ≥100 iu/l 14 ± 2 days after the first eryaspase infusion [median AEA 511 iu/l; interquartile range (IQR), 291-780], whereas six of nine (66.7%) patients had AEA ≥100 iu/l 14 ± 2 days after the fourth infusion (median AEA 932 iu/l; IQR, 496-163). The mean terminal half-life of eryaspase following the first infusion was 15.3 ± 15.5 days. Few asparaginase-related adverse events were reported; five patients (9.1%) developed clinical allergy associated with enzyme inactivation. Replacement therapy was successfully completed in 50 patients (90.9%). Eryaspase was well tolerated, and most patients had AEA levels above the therapeutic target after the first infusion. The half-life of eryaspase confirmed that a 2-week schedule is appropriate.
引用
- Lynggaard LS, Vaitkeviciene G, Langenskiöld C, et al. Asparaginase encapsulated in erythrocytes as second-line treatment in hypersensitive patients with acute lymphoblastic leukaemia. Br J Haematol. 2022. PMID: 35344210. doi:10.1111/bjh.18152
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。